Logo image of 1MRNA.MI

MODERNA INC (1MRNA.MI) Stock Fundamental Analysis

BIT:1MRNA - Euronext Milan - US60770K1079 - Common Stock - Currency: EUR

23.49  +1.24 (+5.6%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to 1MRNA. 1MRNA was compared to 71 industry peers in the Biotechnology industry. The financial health of 1MRNA is average, but there are quite some concerns on its profitability. While showing a medium growth rate, 1MRNA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year 1MRNA has reported negative net income.
In the past year 1MRNA has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: 1MRNA reported negative net income in multiple years.
In multiple years 1MRNA reported negative operating cash flow during the last 5 years.
1MRNA.MI Yearly Net Income VS EBIT VS OCF VS FCF1MRNA.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B

1.2 Ratios

1MRNA has a Return On Assets of -25.18%. This is in the better half of the industry: 1MRNA outperforms 63.38% of its industry peers.
Looking at the Return On Equity, with a value of -32.67%, 1MRNA is in the better half of the industry, outperforming 64.79% of the companies in the same industry.
Industry RankSector Rank
ROA -25.18%
ROE -32.67%
ROIC N/A
ROA(3y)-6.14%
ROA(5y)4.17%
ROE(3y)-7.66%
ROE(5y)6.83%
ROIC(3y)N/A
ROIC(5y)N/A
1MRNA.MI Yearly ROA, ROE, ROIC1MRNA.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

1.3 Margins

Looking at the Gross Margin, with a value of 68.70%, 1MRNA is in the better half of the industry, outperforming 70.42% of the companies in the same industry.
1MRNA's Gross Margin has declined in the last couple of years.
1MRNA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.55%
GM growth 5YN/A
1MRNA.MI Yearly Profit, Operating, Gross Margins1MRNA.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

5

2. Health

2.1 Basic Checks

1MRNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for 1MRNA has been increased compared to 1 year ago.
Compared to 5 years ago, 1MRNA has more shares outstanding
The debt/assets ratio for 1MRNA has been reduced compared to a year ago.
1MRNA.MI Yearly Shares Outstanding1MRNA.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
1MRNA.MI Yearly Total Debt VS Total Assets1MRNA.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.2 Solvency

1MRNA has an Altman-Z score of 2.82. This is not the best score and indicates that 1MRNA is in the grey zone with still only limited risk for bankruptcy at the moment.
With an excellent Altman-Z score value of 2.82, 1MRNA belongs to the best of the industry, outperforming 80.28% of the companies in the same industry.
1MRNA has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
1MRNA has a better Debt to Equity ratio (0.00) than 90.14% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.82
ROIC/WACCN/A
WACC10.22%
1MRNA.MI Yearly LT Debt VS Equity VS FCF1MRNA.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B

2.3 Liquidity

1MRNA has a Current Ratio of 3.67. This indicates that 1MRNA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.67, 1MRNA is in the better half of the industry, outperforming 74.65% of the companies in the same industry.
1MRNA has a Quick Ratio of 3.62. This indicates that 1MRNA is financially healthy and has no problem in meeting its short term obligations.
1MRNA has a better Quick ratio (3.62) than 76.06% of its industry peers.
Industry RankSector Rank
Current Ratio 3.67
Quick Ratio 3.62
1MRNA.MI Yearly Current Assets VS Current Liabilites1MRNA.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 25.22% over the past year.
The Revenue for 1MRNA has decreased by -52.75% in the past year. This is quite bad
The Revenue has been growing by 122.01% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)25.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-629.09%
Revenue 1Y (TTM)-52.75%
Revenue growth 3Y-44.04%
Revenue growth 5Y122.01%
Sales Q2Q%-65.64%

3.2 Future

1MRNA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.49% yearly.
1MRNA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 20.30% yearly.
EPS Next Y-11.66%
EPS Next 2Y7.21%
EPS Next 3Y8.93%
EPS Next 5Y18.49%
Revenue Next Year-32.38%
Revenue Next 2Y-9.14%
Revenue Next 3Y0.54%
Revenue Next 5Y20.3%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
1MRNA.MI Yearly Revenue VS Estimates1MRNA.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5B 10B 15B
1MRNA.MI Yearly EPS VS Estimates1MRNA.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10 20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for 1MRNA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for 1MRNA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
1MRNA.MI Price Earnings VS Forward Price Earnings1MRNA.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
1MRNA.MI Per share data1MRNA.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.21%
EPS Next 3Y8.93%

More info and screens

0

5. Dividend

5.1 Amount

1MRNA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MODERNA INC

BIT:1MRNA (4/24/2025, 7:00:00 PM)

23.49

+1.24 (+5.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-14 2025-02-14/bmo
Earnings (Next)05-01 2025-05-01/bmo
Inst Owners73.88%
Inst Owner ChangeN/A
Ins Owners5.45%
Ins Owner ChangeN/A
Market Cap9.08B
Analysts64.24
Price Target48.43 (106.17%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)47.64%
Min EPS beat(2)-6.26%
Max EPS beat(2)101.54%
EPS beat(4)3
Avg EPS beat(4)28.71%
Min EPS beat(4)-6.26%
Max EPS beat(4)101.54%
EPS beat(8)6
Avg EPS beat(8)1.03%
EPS beat(12)8
Avg EPS beat(12)2.8%
EPS beat(16)11
Avg EPS beat(16)3.24%
Revenue beat(2)2
Avg Revenue beat(2)23.24%
Min Revenue beat(2)0.45%
Max Revenue beat(2)46.04%
Revenue beat(4)4
Avg Revenue beat(4)48.29%
Min Revenue beat(4)0.45%
Max Revenue beat(4)78.74%
Revenue beat(8)8
Avg Revenue beat(8)36.49%
Revenue beat(12)10
Avg Revenue beat(12)27.34%
Revenue beat(16)12
Avg Revenue beat(16)19.08%
PT rev (1m)-8.87%
PT rev (3m)-34.5%
EPS NQ rev (1m)-0.01%
EPS NQ rev (3m)-3.55%
EPS NY rev (1m)-4.53%
EPS NY rev (3m)-13.03%
Revenue NQ rev (1m)-5.27%
Revenue NQ rev (3m)-59.37%
Revenue NY rev (1m)-0.76%
Revenue NY rev (3m)-26.81%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.19
P/FCF N/A
P/OCF N/A
P/B 0.95
P/tB 0.96
EV/EBITDA N/A
EPS(TTM)-8.16
EYN/A
EPS(NY)-9.11
Fwd EYN/A
FCF(TTM)-9.22
FCFYN/A
OCF(TTM)-6.83
OCFYN/A
SpS7.36
BVpS24.79
TBVpS24.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.18%
ROE -32.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.7%
FCFM N/A
ROA(3y)-6.14%
ROA(5y)4.17%
ROE(3y)-7.66%
ROE(5y)6.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.55%
GM growth 5YN/A
F-Score5
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 556.09%
Cap/Sales 32.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.67
Quick Ratio 3.62
Altman-Z 2.82
F-Score5
WACC10.22%
ROIC/WACCN/A
Cap/Depr(3y)261.63%
Cap/Depr(5y)224.68%
Cap/Sales(3y)14.96%
Cap/Sales(5y)10.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-629.09%
EPS Next Y-11.66%
EPS Next 2Y7.21%
EPS Next 3Y8.93%
EPS Next 5Y18.49%
Revenue 1Y (TTM)-52.75%
Revenue growth 3Y-44.04%
Revenue growth 5Y122.01%
Sales Q2Q%-65.64%
Revenue Next Year-32.38%
Revenue Next 2Y-9.14%
Revenue Next 3Y0.54%
Revenue Next 5Y20.3%
EBIT growth 1Y11.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.67%
EBIT Next 3Y12.82%
EBIT Next 5Y18.31%
FCF growth 1Y-6.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3.66%
OCF growth 3YN/A
OCF growth 5YN/A